- $182.21bn
- $227.49bn
- $36.75bn
FDA proposes to withdraw Amgen's drug for rare autoimmune diseases over effectiveness (updated)
FDA proposes to withdraw Amgen's rare autoimmune disease drug
Brief: FDA Says CDER Proposed To Withdraw Approval Of Tavneos
Brief: OpenAI launches AI model GPT-Rosalind for life sciences research
Amgen's lung cancer drug tarlatamab wins China approval
U.S. RESEARCH ROUNDUP-Comstock Resources, Trustmark, Viasat
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Truist cuts Viridian PT after eye disease trial data
U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
Truist raises Amgen PT on expected Q1 beat, obesity focus
Brief: Amgen Inc CEO Robert A. Bradway 2025 Total Compensation $24.7 Million
Viridian slides as Amgen data raises competition fears
Brief: Amgen Reports Positive Topline Phase 3 Results For Subcutaneous Tepezza In Thyroid Eye Disease
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zai Lab Announces Global Clinical Trial Collaboration And Supply Agreement To Evaluate Novel Dll3 Adc, Zocilurtatug Pelitecan, In Combination With A Bispecific T-Cell Engager Therapy